Sanofi's Tzield received expanded US Food and Drug Administration approval to delay the onset of stage 3 type 1 diabetes in children as young as one, a significant expansion for the first disease-modifying therapy in this class.
"This approval opens an important new chapter in diabetes care for young children with stage 2 type 1 diabetes and their families,” Kimber Simmons, a professor of pediatrics at the Barbara Davis Center, said in a statement.
The approval, granted under a priority review, was supported by safety and pharmacokinetic data from the 23-participant PETITE-T1D Phase 4 study. Tzield, a CD3-directed monoclonal antibody, was first approved in November 2022 for patients aged eight and older. The drug also holds orphan drug designation, a status for treatments of diseases affecting fewer than 200,000 people in the US.
The expanded indication could significantly increase Tzield's addressable market and bolster Sanofi's revenue stream from its growing diabetes franchise. The approval solidifies Sanofi's leadership in autoimmune disease and may attract further investment in its pipeline ahead of potential new indications for Tzield.
Type 1 diabetes is a progressive autoimmune disease that impairs the body's ability to regulate blood sugar. The new approval allows for intervention in stage 2 of the disease, defined by the presence of two or more T1D-related autoantibodies and abnormal blood sugar levels, before the clinical diagnosis of stage 3.
"This approval underscores the importance of targeting the immune system early in autoimmune type 1 diabetes, aiming to impact its natural progression by delaying the loss of insulin production in the pancreas,” said Christopher Corsico, Global Head of Development at Sanofi.
Tzield is also approved for patients eight and older in the European Union (under the brand name Teizeild), the UK, China, and Canada, among other countries. Sanofi is also seeking FDA approval for Tzield to delay the progression of stage 3 T1D in patients eight years of age and older who have been recently diagnosed.
The approval provides a new, earlier intervention option for a high-risk pediatric population, potentially changing the standard of care. Investors will now watch for Sanofi's upcoming earnings reports for initial sales figures from this expanded demographic and any updates on the pending FDA review for Tzield in recently diagnosed stage 3 T1D patients.
This article is for informational purposes only and does not constitute investment advice.
